ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PLX Protalix BioTherapeutics Inc

2.56
-0.02 (-0.78%)
29 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Protalix BioTherapeutics Inc AMEX:PLX AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -0.78% 2.56 2.62 2.525 2.59 447,220 00:00:00

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

05/02/2013 4:43pm

GlobeNewswire Inc.


Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart


From Mar 2020 to Mar 2025

Click Here for more Protalix BioTherapeutics Charts.

Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx®.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect" and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Factors that might cause material differences include, among others, risks relating to potential strategic alternatives. The statements in this release are valid only as of the date hereof and we disclaim any obligation to update this information.

CONTACT: Investor Contact
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com

1 Year Protalix BioTherapeutics Chart

1 Year Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart